Skip to main
BWAY
BWAY logo

Brainsway (BWAY) Stock Forecast & Price Target

Brainsway (BWAY) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BrainsWay Ltd has exhibited significant growth potential, as evidenced by a greater than 50% increase in equipment utilization since the establishment of its investment arrangement. The company is benefiting from strategic investments that are poised to enhance revenue growth and is witnessing a growing acceptance of pay-per-use models along with potential demand from neurologist specialists. Additionally, the optimized clinic infrastructure for Deep TMS therapy positions BrainsWay favorably alongside existing treatment options, suggesting a robust market acceptance and diversification of revenue streams.

Bears say

The negative outlook on BrainsWay's stock is primarily driven by several fundamental risks associated with its business model, particularly the slower-than-projected uptake of Deep TMS systems. Additionally, the company faces challenges in expanding reimbursement and market access, which could hinder revenue growth. Furthermore, the inability to advance its technology into other therapeutic indications, along with potential long-term dilution risk, raises concerns about the company’s future financial stability and growth potential.

Brainsway (BWAY) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Brainsway (BWAY) Forecast

Analysts have given Brainsway (BWAY) a Buy based on their latest research and market trends.

According to 2 analysts, Brainsway (BWAY) has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Brainsway (BWAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.